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Abstract
Angiogenesis and vasculogenesis are two very important processes in the development 
and maintenance o f mammalian health. All structures o f the body (human or animal) 
need certain essential elements in order to live thrive and maintain. The angiogenic role is 
to supply and support tissue with ample vasculature, thus providing a route o f access for 
the transportation o f essential nutrients and the removal o f waste in a sustained fashion. 
Just like normal tissue, tumorogenic tissue is no exception; neoplastic tissue has the same 
nutritional requirements which must be supported via vascularization.
Vascular endothelial growth factor (VEGF) has been shown to be a key mediating factor 
in the underlying cascade o f chemical events leading to angiogenesis, which makes it a 
very important precursor molecule for early neoplasia detection. The overall purpose o f 
this study was to establish circulatory baseline VEGF levels in healthy dog models. 
Baseline levels o f VEGF in plasma will aid as a model in detection, comparison and 
evaluating o f disease progression in sled dogs.
There were significant differences between male and female dogs and exercising males 
and exercising females. A significant factor affecting baseline levels was gender. In 
addition there is some data which suggest that breed may play a role in baseline VEGF 
levels.
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1Chapter 1 
INTRODUCTION
Angiogenesis and vasculogenesis are two processes important to developing mammals. 
These two processes are mediating factors within the embryonic cardiovascular system, 
which is the first organ to undertake morphological development (Risau and Flamme, 
1995). Vasculogenesis is the term used to describe the vascular development during 
embryogenesis. During vasculogenesis, vascular plexus formation (capillary bed 
development) arises from angioblasts o f progenitor endothelial cells (ECs), which 
differentiate into mesodermal embryonic tissue. Following differentiation, angiogenic 
factors activate and refine and/or remodel the unmodulated vasculature which is, at this 
stage, just budding and sprouting tubular endothelial rolls formed via secondary 
angiogenesis. The vascular modeling forms these rolls into fully developed and 
functional vessels which increase in size over time (Risau, 1997). Once vascular 
maturation is achieved, smooth muscle cells, called pericytes, migrate and adhere to the 
outer basal membrane o f the matured vessel. The pericytes serve as stabilizers for the 
developed vasculature.
The developing angiogenic vasculature responds to perturbation o f the growing em bryo’s 
demand for oxygen, glucose and other nutrients. Angiogenesis in matured or adult 
vasculature also responds to other sources o f perturbation, specifically the metabolic 
needs o f tissue and organs, including perturbations o f hypoxia and ischemia. Excessive or 
insufficient angiogenesis (unregulated) plays a major role in the pathogenesis o f many 
diseases: rheumatoid arthritis, blindness (ocular disease and hypertrophy), complication 
with AIDS patients, stroke, heart disease, ulcers scleroderma and infertility in women 
(Folkman, 1995; Griffioen and Molema, 2000; Griffioen et al., 1998; Molema and 
Griffioen, 1998). Vasculogenesis and angiogenesis both are biological processes which 
are predicated on many different chemical factors: cytokines, cell adhesion molecules 
(CAMs), components o f the extracellular matrix (ECM), surface cell receptors, various 
proteins and angiogenic/mitogenic growth factors (Risau, 1997).
1.1 Proteins and Their Role in Cellular Signaling
Proteins are in many respects the main chemical mediators o f biological systems. The 
body uses protein for storage, structural support, enzymatic catalyzation o f both anabolic 
and catabolic metabolism, cell to cell signaling, muscle movement, transportation and 
elimination o f cellular waste products and immunological defense o f invading foreign 
substances. The importance of proteins and their function in biological systems is 
apparent from the Greek derivation o f protein, proteios, meaning “first place” (Campbell
et al., 1999). A brief overview o f various proteins and the roles they play in biological 
systems is displayed in Table 1.1.
Table 1.1. Protein functions within biological systems and their respective roles 
(Adapted from Campbell et al.,1999).
TYPE OF 
PROTEIN
BIOLOGICAL
FUNCTION
EXAMPLE
Structural Support: cellular 
and noncellular
Collagen and elastin provide structural 
framework for connective tissue. Keratin 
provides the framework for hair and skin.
Storage Amino acid storage Ovalbumin is an amino acid source used for 
developing embryos. Casein in breast milk is 
the major source o f protein utilized by infant 
mammals.
Transport Transportation o f 
chemicals
Hemoglobin in the blood transports oxygen 
form the lungs to various parts o f the body.
Hormonal Coordination of 
systemic activities.
Insulin secreted from the pancreas regulates the 
systemic concentration o f glucose in the blood.
Cell Signaling Cell to cell
chemical
communication.
Neurotransmitters bind to receptors o f nearby 
nerve cells which propagates stimuli along to 
other regions o f the body. Acetylcholine is a 
common neurotransmitter.
Contractile Movement Actin and myosin are contractile proteins 
which are responsible for the movement of 
muscles. Other contractile proteins are 
responsible for the movement o f cilia and 
flagella.
Immunoglobins Defense against 
foreign substances
Antibodies are responsible for the main defense 
against foreign bacteria and viruses.
Enzymes Selective 
acceleration of 
chemical 
Reactions.
Urease selectively catalyzes the breakdown o f 
urea for excretion in the urine.
4Winner o f the Nobel Prize in 1971, Earl W. Sutherland was the pioneer o f our basic 
understanding o f cellular events which most modern cellular signaling research is based. 
At Vanderbilt University, Sutherland and his colleagues studied the cellular elucidation 
o f how epinephrine depolymerizes glycogen stores within hepatocytes and skeletal 
muscles for the release o f glucose to be used for energy. For simplicity, Sutherland 
characterized cellular signaling events into three basic events: ( 1) cellular signal 
reception, (2) signal transduction or propagation and (3) the cellular response to the 
signal reception.
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Figure 1.1. Overview o f basic cellular events involved in cellular signaling. Cellular 
events can be broken down into three major events: reception, transduction and cellular 
response. Reception involves the binding o f a signal molecule that causes a 
conformational change in the adhesion surface cell receptor. The conformational change 
causes a cascade o f chemical interactions (transduction) involving numerous molecules; 
each molecule brings about a conformational change in the next molecule. The last 
molecule in the pathway is the molecule which elicits or propagates the cellular response 
(Adapted from Campbell et al., 1999).
As previously described in Table 1.1, there are many areas within protein chemistry 
pertaining to biological systems. The remainder o f this chapter will focus on cellular 
signaling and protein functions pertaining to neovascularization during embryogenesis 
and angiogenesis. These processes serve as a molecular framework for the understanding 
o f normal and abnormal cellular mechanisms involving vasculature.
1.2 Angiogenesis
The term angiogenesis was first used in 1787 by a British surgeon, Dr. John Hunter 
(Encyclopedia Britannica, 2003 ed.), who was explaining the blood vessel growth in 
reindeer antlers. Angiogenesis is literally taken to mean the forming o f new blood vessels 
(capillaries) or neovascularization. “Angi”- translated from Greeks meaning vessel and -  
“genesis” refers to the creation or forming o f a given entity. Angiogenesis is a complex 
process involving many signaling pathways leading to the neovascularization or 
revascularization o f specific targeted areas or tissue. It is at the tissue level that the role o f 
angiogenesis is made known. All structures o f the body (human or animal) have to have 
certain essential elements in order to live, thrive and maintain. The angiogenic role is to 
supply and support the vasculature in order to provide a route o f access for the 
transportation o f essential elements and the removal o f waste in a sustained fashion. 
Without a properly functioning vasculature, tissue is subjected to various insults such as 
hypoxia and ischemia, both o f which lead to a cascade o f deleterious effects on the 
surrounding milieu. This phenomenon is apparent in the study o f embryology.
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6Angiogenesis in the developing embryo and fetus is referred to as vasculogenesis (Risau 
and Famme, 1995), the forming o f the body’s vascular system. The internal infrastructure 
is essential in vasculogenesis in order for the developing embryo and fetus to grow and 
develop while receiving the proper balance o f “nutrition” brought in via the vascular 
system. Embryonic waste is filtered out through the same vascular system.
Angiogenesis is an essential part o f a developing embryo; however, this does not hold 
true in adults. Just like a developing embryo, adults need the same network o f vasculature 
to bring in oxygen, glucose, nutrients and to remove waste products. The difference is 
that the adult vascular system has reached maturation and is, thus, functioning at a normal 
level without the added neovascularization that angiogenesis employs. As adults, 
angiogenesis is only initiated under certain instances o f insults or threats to the normoxic 
functioning o f the body, such as with insults o f hypoxia, ischemia, neoplasia or focal 
tissue insult (Folkman, 1995; Breier, 2000). All insults are inducers o f angiogenesis and 
follow the same or similar signal transductive cascades o f activation.
The underlying processes involved with the formation o f neovascularization or 
vasculogenesis occurs in a well orchestrated cascade o f events initiated at the molecular 
level and terminated at the macroscopic level. Diseased (tumorogenic) or injured tissue 
(laceration) release various angiogenic and mitogenic proteins as a direct response to the 
insult. The same angiogenic and mitogenic proteins are released during embryonic
development in utero. These proteins, collectively called growth factors, diffuse out 
from their source o f origin into the surrounding tissue. Once diffused, these growth 
factors migrate and recognize surface cell receptor amobile molecules (SCRAMs), which 
are located on the outer surface o f endothelial cells (ECs). The ECs line the outer portion 
o f nearby preexisting vasculature: blood vessels, capillary beds, veins and arteries 
(dependent upon location). The binding o f growth factors to their respective SCRAM 
sites on ECs is a regio-specific process. As a result o f the growth factor and SCRAM 
synergism, each growth factor recognizes only one or two specific SCRAMs. Once 
binding has occurred between the growth factor and the SCRAM, the EC becomes 
activated. The activation o f ECs is the result o f a signal transductive process that relays 
from the ECs surface to the nucleus, and as a result, the ECs cellular machinery induces 
production o f various enzymes called metalloproteinases (Brown and Giavazzi, 1995; 
Brown and Hudlicka, 2003). Metalloproteinases are a select group o f protease enzymes 
which attack and degrade the basel basement membrane o f ECs. This chemical 
degradation includes the digestion o f specialized cells called pericytes (Folkman and 
Shing 1992), which line the outer layer o f ECs. Resting nonproliforative ECs are tightly 
controlled in a state o f quiescent. In other words, pericytes thwart additional EC 
proliferation (Antonelli-Orlidge et al., 1989; Denekamp and Hill, 1991). The degradation 
results in small tears or holes in the vessel where the endothelial lining has been 
compromised.
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In addition to signaling the production o f the metalloproteinase, the nucleus has received 
signals for the ECs to proliferate. The now active proliferation o f ECs leads to the 
sprouting and intussusceptive buds o f ECs from the degraded holes in the parent vessel 
(Figure 1.2; Risau, 1997). Specialized proteases called matrix metalloproteinase or 
MMPs are produced to dissolve intruding tissue in the path o f sprouting angiogenic buds. 
The buds o f ECs start to compile into stacks or rolls forming small vesicle tubes. The 
tissue matrix which has been dissolved by MMPs starts to form back around the 
neovascular tubes. The newly formed tube vesicles form loops and connect with other 
neovascular tubes, thus establishing a circulatory pathway. The newly formed vasculature 
is now anchored and stabilized by the smooth muscle cell pericytes. These cells again 
provide support and protection from further degradation by MMPs. The end result is a 
neovascular pathway through which blood, and consequently, oxygen, glucose and 
nutrients can flow; these events are schematically summarized in figure 1.2 .
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Figure 1.2. Generalized cascade o f events leading to the formation o f new vasculature. 
Normal embryonic development and abnormal tumor development both utilize similar 
cascading events in the development and maturation o f their supporting vasculature. The 
events o f development are as follow: (1) Release o f angiogenic proteins or growth factors 
(GFs) which diffuse out into the surrounding tissue. (2) The GFs are released where they 
recognized certain GF receptors (SCRAMs). (3) Once GFs bind to their respective 
receptors, they activate ECs, which cause intracellular signaling from the cell’s surface to 
the nucleus. The signaling initiates production o f various enzymes called 
metalloproteinases (MPs). (4) The MPs degrade the outer basement membrane o f existing 
blood vessels, thus leaving tiny holes in the vessel walls. (5) Mitogenic ECs begin to
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proliferate and dissolve through the tiny holes made by the MPs, where they migrate 
forward. (6) The sprouting vesicle o f ECs is pulled forward via specialized enzymes or 
integrins (avb3 and avb5). (7) Remodeling o f the extra cellular matrix is mediated by 
matrix metalloproteinases (MMPs). The MMPs degrade the extra cellular matrix so the 
newly forming vesicles have room to grow. The matrix quickly adheres back around the 
forming vesicle after vesicle extension. (8) ECs role and stack on top o f one another and 
start to form tubes. (9) Newly formed tubes hook up and grow into other tubes near by. 
They form a loop with one another through which blood can begin to circulate. (10) The 
newly formed vasculature is now stabilized by specialized muscle cells called pericytes.
There are many stimulators which initiate the events o f angiogenesis. M ost o f these 
stimulators are specific proteins called growth factors which were referred to previously. 
The idea o f specific proteins mediating the events o f angiogenic growth was first 
proposed by Judah Folkman back in 1971 (Folkman, 1971). Folkman proposed that if 
specific proteins (GFs) existed, then those proteins could help in the elucidation of 
angiogenic abnormalities. It was not until 1984 that the first o f these specific angiogenic 
proteins was isolated and characterized (Shing, 1988; Shing and Klagsbrun, 1984). Since 
the first characterization, many angiogenic genes and gene products have been isolated, 
purified and produced via recombinant DNA methodology. This has enabled a plethora 
o f new data characterizing many new molecular angiogenic stimuli. These angiogenic 
stimulatory molecules (ASM) can be divided into seven major groups o f classification: 
(1) growth factors, (2) proteases, (3) trace elements or metals, (4) oncogenes, (5) 
cytokines, (6) molecules involved in cellular signal transduction (STMs), and (7) 
endogenous angiogenic inducers (Table 1.2).
Table 1.2. Endogenous Growth Factors And Angiogenic Stimulators (Adapted from 
Brem. 1999).
Growth Factors Angiogenin
Angiotropin
Epidermal growth factor (EGF)
Fibroblast growth factor: basic and acidic (bFGF 
and aFGF)
Granulocyte colony-stimulating factor (GCSF) 
Hepatocyte growth factor/ scatter factor 
(HGF/SF)
Platelet-derived growth factor (PDGF)
Tumor necrosis factor alpha (aTNF)
Vascular Endothelial growth factor (VEGF)
Proteases Cathepsin 
Gelatinase A, B 
Stromelysin
Urokinase-type plasminogen activator (uPA)
Trace Element: Metal Copper
Oncogenes c-myc
ras
c-src
v-raf
c-jun
Signal Transductive 
Enzymes
Thymidine phosphorylase 
Farnesyl transferase 
Geranylgeranyl transferase
Cytokines Interleukin-1 
Inerleukin-6 
Interleukin-8
Endogenous Angiogenic 
Inducers
Alpha v Beta 3 integrin 
Angiopoietin-1 
Angiostatin II (ATI receptor) 
Endothelin (ETB receptor) 
Erythropoietin
Hypoxia and Ischemia (perturbation) 
Nitric oxide synthase 
Platelet-activating factor 
Prostaglandin E 
Thrombopoietin
All o f the previously mentioned categories or angiogenic stimulators (Table 1.2) are 
currently under study at numerous laboratories (Brem, 1999). Among these categories, 
growth factors seem to be the most popular due to their dual role o f embryonic 
angiogenesis and angiogenic malignancies. The most widely studied growth factors are: 
acidic and basic fibroblast growth factor (aFGF and bFGF), vascular endothelial growth 
factor (VEGF) which is sometimes called vascular permeability factor (VPF), platelet 
derived-endothelial cell growth factor (PD-ECGF), alpha and beta transforming growth 
factor (aTGF and PTGF), angiogenin, and alpha tumor necrosis factor (aTNF). A 
detailed list o f these polypeptides and their respective functions is listed in Table 1.3.
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Table 1.3. Angiogenic Polypeptides: Structure and Biological Function (Adapted from 
Y. Shing and J. Folkman, 1992).
Growth
Factors
MW EC
Mitogenicity
Angiogenic Biological 
Activities and Functions
bFGF
aFGF
18kDa
16.4kDa
Yes
Yes
• Mitogenicity found in many 
different cell types (Burgess and 
Maciag 1986; Folkman and 
Klagsbrun, 1987; Gospodarowicz, 
1990; Klagsbrun and D ’Amore, 
1991; Rifkin and Moscatelli, 1989; 
Thomas, 1987).
• Binds to heparan sulfate 
proteoglycan (Vlodavsky et al., 
1987; Baird and Ling, 1987) and 
copper (Shing, 1988).
• Stimulates EC migration and tube 
formation (Montesano et al.,
1986).
• Stimulates protease production and 
plasminogen activator (Moscatelli 
et al., 1986; Presta et al., 1986).
• Induces embryogenesis 
(Kimmelman and Kirschner, 1987; 
Slack et al., 1987).
VEGF/VPF 45kDa Yes • Proliferatory activation which is 
highly specific for ECs (Ferrara 
and Henzel, 1989).
• Induces secretory proteins (Conn et 
al, 1990; Myoken et al., 1991; 
Rosenthal et al., 1990) and 
increases vascular permeability 
(Connolly et al., 1989).
• Mediates plasminogen activation 
and inhibition in ECs (Pepper et 
al., 1991).
• Structurally homologous to PDGF 
(Conn et al., 1990; Keck et al.,
1989; Tischer et al., 1991).
PD-ECGF 45kDa Yes • Stimulates DNA synthesis in ECs 
and induces chemotaxis (Ishikawa 
et al., 1989).
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Table 1.3. Continued
a-TGF 5.5kDa Yes • Switches normoxic ECs to transformed 
phenotype (Derynck, 1990).
• Recognizes and binds to EGF receptor 
(Derynck. 1990).
Angiogenin 14. lkD a None
established
• EC formation o f diacylglycerol (Bicknell 
and Vallee, 1988) and secretion of 
prostacylin (Bicknell and Vallee, 1989) via 
phospholipase C and phospholipase A2 
activation, respectively.
• Ribonucleolytic activity which is essential 
for neovascularization (Shariro et al.,
1986; St. Clair et al., 1987).
a-TGF 25kDa No • Binds to copper (Roberts and Sporn, 
1990).
• Stimulation o f extracellular matrix 
production (Roberts and Sporn, 1990).
• Monocytic chemotatability (Roberts and 
Sporn, 1990).
P-TNF 55kDa No • ECs stimulation o f bFGF and its secretion 
(Okmaura et al., 1991).
• Monocytic chemotatability (Beutler and 
Cerami, 1986).
• Macrophage activation (Beutler and 
Cerami, 1986).
All polypeptide growth factors and angiogenic stimulator data were determined via chick 
embryo choriallantoic membrane assay (ChMA), corneal micropocket assay (CMA) 
and/or hamster cheek pouch assay (HCPA). For further review and assay protocols see 
the following references: bFGF (Montesano et al., 1986; Shing et al., 1985), aFGF (Lobb 
et al., 1985; Thomas et al., 1985), VEGF/VPF (Connolly et al., 1989; Kimmelman and 
Kirschner, 1987; Leung et al., 1989), PD-ECGF ( Ishikawa et al., 1989), a-TGF
(Schreiber et al., 1986), Angiogenin (Fett et al., 1985), P-TGF (Roberts et al., 1990), a- 
TNF (Frater-Schroder et al., 1987; Leibovich et al., 1987).
1.3 Vascular Endothelial Growth Factor (VEGF/VPF)
Vascular endothelial growth factor (VEGF) (Ferrara and Henzel, 1989), also referred to 
as vascular permeability factor (VPF) (Senger et al., 1983) or vasculotropin (Plouet et al., 
1989), has very specific properties with respect to ECs. VEGF is a heparin-binding 
polypeptide glycoprotein with mitogenic and angiogenic ECs specificity. In addition, 
VEGF has an enhanced ability for vascular permeability specific for ECs. VEGF 
recognizes and binds to specific SCRAMs located on the outer membrane o f ECs. VEGF 
is found throughout the body in many different cell types. In normal tissue VEGF has 
been found in activated macrophages (Fava et al., 1994), keratinocytes (Brown et al., 
1992a), renal glomerular visceral epithelium (Brown et al., 1992b; Iijima et al., 1993), 
smooth muscle cells (Ferrara et al., 1991), hepatocytes (Monacci et al., 1993), mesangial 
cells (Brown et al., 1992b; Iijima et al., 1993), leydig cells ( Shweiki et al., 1993), 
embryonic fibroblast, bronchial and choroid plexus epithelium (Breier et al., 1992; 
Pertovaara et al., 1994). In addition, VEGF has been shown to play important roles in 
varying types o f tumors (Connolly, 1991; Ferrara et al., 1992; Neufeld et al., 1992; Schott 
and Morrow., 1993).
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1.3.1 Vascular Endothelial Growth Factor: Structure
Structurally VEGF is a homodimeric polypeptide which occurs in at least five different 
isoforms in humans (Breier, 2000; Veikkola et al., 1999): VEGF145, VEGF165, VEGFi89 
and VEGF206 respectively (also resported as VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
VEGF-E). All five isoforms are derived through alternate mRNA splicing variants o f a 
single gene (Breier, 2000; Veikkola and Alitalo, 1999). Besides their amino acid 
sequence, these isoforms differ primarily in their heparin binding which may also affect 
their extracellular diffusion rates (Breier, 2000). V EGF145 or VEGF-A is the founding 
member o f the VEGF family o f growth factors (Figure 1.3).
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Figure 1.3. Structure o f the dimeric form o f V EGF145/VEGF-A. Helices as shown in 
pink, beta sheets are shown in yellow/orange and loop regions are shown in white. Three 
dimensional analysis was conducted using RasM olR computer simulation.
VEGF shows structural and amino acid sequence homology with placental growth factor 
(P1GF) and transforming growth factor (TGF), which are growth factors having 
mitogenic and angiogenic activities. However, VEGF and P1GF are more closely related 
to one another as compared to TGF due to their ability to bind specific tyrosine kinase 
receptors (TKRs).
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1.3.2 VEGF Tyrosine Kinase Receptors
As previously stated, angiogenic and mitogenic cellular activities are mediated by many 
different cellular molecules (Breier, 2000; Risau, 1997), and specifically growth factors 
and their cellular receptors (Risau, 1997). There is ample evidence that suggests that 
endothelial-specific tyrosine kinase receptors and their ligands mediate these complex 
biological processes (Breier, 2000; Neufeld et al., 1999). VEGF binds several TKRs: 
VEGF receptor one or fetal liver transferase one (VEGFR-1 or F it-1), VEGF receptor two 
or fetal liver kinase one or kinase domain receptor (VEGFR-2 or Flk-l/K D R), VEGF 
receptor three or fetal liver transferase four (VEGFR-3 or Flt-4) and neuropilin (Figure 
1.4). In addition to the VEGF signaling pathway, another signaling pathway has been 
found to be governed by angiopoietin and its family o f receptors: Ang-1, Ang-2, Ang-3 
and the Tie2 receptor (Figure 1.4).
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Figure 1.4. Receptors involved in angiogenic and mitogenic cascade activation, ECs 
signaling system (Adapted from Breier et al., 1997; Breier, 2000). The VEGF family o f 
receptors are characterized by an extracellular immoglobulin-like domain (Ig) which 
makes these receptors soluble (sFlt-1) during laboratory extraction. The Ig domain is 
comprised o f seven Ig loops exposed in the cytosol of the extracellular membrane. 
Separated only by the transmembrane (TM), is the split-kinase (S-K) domain embedded 
within the EC. In contrast to the VEGF receptors, the Angiopoietin receptors (Tie-1 and 
Tie-2, respectively) have only one Ig extracellular domain followed by three epidermal 
growth factor-like (EGF) repeats and three fibronectin-like domains (FN). Across the TM 
from these domain lies only a single kinase domain embedded in the EC. Neuropilin is 
not structurally related to either o f the VEGF or the Angiopoietin receptors. Neuropilin 
seems to only have binding interactions with the V EG F165 isomer (Breier et al., 1997; 
Breier, 2000).
Gene expression studies have been instrumental in the current understanding o f the 
V E G F  and angiopoietin EC receptor system during embryonic development. It appears 
that V E G F  (V E G F -A  or VEGF145) is essential for the early development o f vasculature
(Breier, 2000). Various studies, using knockout mice have revealed that the development 
o f vasculature is lethally thwarted in mice lacking a single VEGF allele, ultimately 
leading to death around day ten (Carmeliet et al., 1996; Ferrara et al., 1996). These 
studies concluded that numerous embryonic processes are adversely affected; the 
formation o f the dorsal aorta (large-vessel vasculature), vascular remodeling o f the yolk 
sac and the secondary sprouting o f capillaries form the dorsal aorta. In addition Carmeliet 
and Ferrara and their colleagues (1996) found that the inactivation o f individual VEGF 
receptors resulted in embryonic death during mid gestation. They determined that these 
receptors act in a very distinct manner. Each receptor has a different function with respect 
to binding and biological activity, leading to phenotypic specificity. For example, the 
mice which were engineered to be deficient in the Flk-1 receptors showed a dramatic 
failure o f vasculogenesis, EC differentiation and hematopoiesis (Shalaby et al., 1995). In 
contrast Fong et al. (1995) found that F it-1 deficient mouse embryos sustained 
abnormally enlarged vasculature resulting from hyperstimulatory angioblast activity. 
Numerous studies indicate that the Flk-1 receptor is the main VEGF receptor governing 
signaling in ECs, and that the F it-1 receptor’s tyrosine kinase domain appears to be 
dispensable during embryonic development (Hiratsuka et al., 1998), suggesting its main 
function is ligand binding in ECs. VEGFR -2/Flk-2 has displayed evidence that it may 
play a role during axonal sprouting and neuronal development during vasculogenesis and 
also following hypoxic or ischemic insults (Jin et al., 2000; Sondell et al., 1999; Terman 
et al., 1992; W alternberger et al., 1994).
Angiopoietin receptors have similar functions analogous to VEGF with a few exceptions. 
Mice lacking the Tie2 receptor displayed underdeveloped vasculature leading to 
embryonic death (Sato et al., 1995; Suri et al., 1996). The Ang-1 and Tie2 deficient mice 
showed normal embryonic vascular development, indicating that the Ang-1 /Tie2 
signaling system is downstream with respect to the VEGF receptor system (Breier, 2000). 
The Ang-1/Tie2 receptor system, however, does show areas o f malicious activity. For 
example, Koblizek and colleagues (1997) found that Ang-1/Tie2 knockout mice 
displayed no evidence o f cardial trabeculation, yolk sac remodeling or sprouting of 
capillaries in neuronal tubes. Thus, suggesting that cardial trabecubation is the result o f 
the Ang-1 /Tie2 involvement in perivascular cardiac cellular recruitment. It has previously 
been shown that Ang-1 is involved with ECs formation o f sprouts in vitro (Koblizek et 
al., 1997). VEGF receptors along with Ang-1 appear to act synergistically during 
angiogenesis, but this relationship does not hold true during vasculogenesis. The 
significance o f the Tie-1 receptor is yet to be established.
1.4 VEGF’s Role in Pathogenesis
As discussed in previous sections, angiogenesis is the sprouting and migration o f 
capillary vessels and is the primary means through which the brain and other organs 
become vascularized. All o f this takes place in embryogenesis and under certain normal 
conditions in adult tissue growth. For example, meticulously controlled angiogenesis 
takes place in wound healing and in the female reproductive cycle. In contrast to normal
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angiogenesis, there are many malignancies which are mediated via angiogenesis and 
mitogenic proteins. Angiogenesis is characterized by the constant proliferation o f ECs 
(Plate et al., 1994). Unregulated EC proliferation is a prominent characteristic o f many 
disease processes, including but not limited to: proliferative retinopathy, rheumatoid 
arthritis, psoriasis, colon polyps, hemangiomas and breast cancer. Angiogenesis must be 
kept under tight biological control in order to avoid abnormal pathogenesis. 
Hyperangiogenic activity and hypoangiogenic activity can both lead to deleterious 
pathological events in vivo (Figure 1.5).
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Figure 1.5 Pathological processes (abnormal) which are angiogenic dependant.
Tissue damage after reperfusion o f hypoxic or ischemic tissue during myocardial 
infarction is angiogenic dependant in that angiogenesis is inadequate. In many other 
diseases angiogenesis is excessive such as solid state tumors and hematological tumors. 
Atherosclerosis, restenosis (cardiovascular disease), Crohn’s Disease and rheumatoid 
arthritis (chronic inflammatory processes), diabetes (diabetic retinopathy), psoriasis, 
endometriosis and adiposity; all are characterized by uncontrolled angiogenesis 
(Griffioen et al., 1998; Griffioen and Molema, 2000; Molema and Griffioen, 1998).
1.5 Neoplasia and Tumors
The onset o f many tumors appears to be mediated by genes encoding various mitogenic 
and angiogenic growth factors, such as VEGF. These genes also coordinate induction o f 
other genes in EC to encode the respective SCRAM growth factor receptor proteins 
(Plate et al., 1994). These pathways appear to be regulated via paracrine mechanisms in 
two o f the VEGF family o f TKRs; V EG FR-1 (F it-1) and VEGFR-2 (Flk-l/KD R), 
respectively (Plate et al., 1994).
Tumors exists as small conglomerations o f ECs during their early stage o f pathogenesis, 
which at this point, the tumor can take on the form o f malignant or benign pathology. The 
point at which the tumor cells switch to the malignant phenotype is a major area o f 
research and to date has not been fully characterized. Tumor cells can remain in a 
nonproliferatory state for weeks or even years (weeks in mice and years in humans).
During this ‘‘dormant” time period, tumor growth is restricted to only a few m m \ At 
some point the tumor cells develop vasculature which is sufficient for prolonged survival, 
but not for the rapid malignant growth o f the parent tumor which is needed to metastasize 
to distant organs o f the body (Folkman and Shing, 1992). The mechanisms mediating 
these events are not clear and previous publications rest on the assumption that tumor 
cells simply release angiogenic factors. This assumption is no longer tenable (Folkman 
and Shing, 1992). While the previous assumption is certainly true, it is but one o f many 
different events mediating tumor angiogenesis. Furthermore, the elucidation as to how 
angiogenic factors such as VEGF and bFGF are released is still poorly understood. One 
major underlying unexplained phenomena is how the release o f angiogenic factors is 
balanced with the release o f angiogenic inhibitors. For example, thrombospondin is an 
angiogenic inhibitory protein (AIP) secreted by normal cells. This endogenous protein 
has previously been shown to be under tight control and down-regulation during 
tumorogenesis (Bouck, 1990; Rastinejad et al., 1989). Such control may be under the 
local control o f tumor suppressor genes. However, even under control via gene 
expression, a shift o f balance or new mutation must occur in order for a stagnant tumor 
cell to turn into an active proliferatory phenotype. This idea is supported by recent 
findings that tumor cells simultaneously secrete plasminogen activators (proteases) and 
their counterparts (plasminogen inhibitors or AIPs). This relationship is a key regulatory 
process which controls proteolysis and ultimately suppresses or fosters the growth of 
angiogenesis leading to tumor growth and metastasis. Steiner (1992) proposed the
25
following mechanisms for the angiogenic switch to the proliferatory phenotype (Figure
Figure 1.6 Proposed mechanisms for the switch to angiogenic phenotype in tumor 
pathogenesis. (1) Various angiogenic molecules are exported out o f the cell: VEGF, 
PDGF, bFGF and other mitogenic growth factors. (2) These angiogenic molecules must 
navigate and migrate through tissue in order to reach the surrounding vasculature. 
Heparan sulfate plays a role in the stabilization o f many growth factor’s migratory 
process. (3) Some o f the migratory growth factors stimulate endothelial cell migration 
and chemotaxis more efficiently than DNA synthesis. (4) Growth factors and other 
angiogenic factors release collagenases and plasminogen activators from endothelial cells 
which degrade the basement membrane o f the parent venule. These proteases are 
responsible for “clearing’' the way for endothelial sprouting and budding. (5) In addition 
to the release o f angiogenic growth factors, tumors may also employ macrophages and 
mast cells which can foster angiogenesis; (6) it is here that macrophages can release 
angiogenic molecules ( a-TNF) which in turn recruit more macrophages. (7) Tumor cells 
also have the ability to secrete various proteases which attack the basement membrane.
(8) bFGF is stored in the extracellular membrane and can be mobilized for the membrane 
degradation. (9) VEGF is an angiogenic factor and is also referred to as a vascular 
permeability factor (VPF) which cause increase permeability in the surrounding capillary
1.6 ).
Basement
M em braneM ast C ell
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beds, which may lead to fibrin leakage into the extracellular space (Dovorak et al., 1988). 
(10& 11) Inhibition o f angiogenic inhibitory factors must be regulated and adequately 
suppressed before angiogenic molecules can diffuse and initiate neovascularization.
Many laboratories are working with the manipulation o f the varying factors mediating 
angiogenesis. There are currently numerous late stage clinical trials involving angiogenic 
inhibitors for cancer therapy and there are clinical trials involving angiogenic inducers 
involving myocardial infarction and stroke patients. These therapies and their unique 
approach to cellular regulation have excellent promise for becoming useful medical 
modalities.
The overall purpose o f my study was to establish circulatory baseline VEGF levels in 
healthy dog models. It is my hope that baseline levels o f VEGF in plasma will aid as a 
comparative model for disease and other angiogenic abnormalities in this animal.
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Chapter 2 
MATERIAL AND M ETHODS
2.1 Animal Models
The Institute o f Animal Use and Care Committee at the University o f Alaska Fairbanks 
approved this study. The animals utilized in this study were racing sled dogs owned and 
under the supervision o f Dr. Arleigh Reynolds. The animals were housed at the Nestle 
Purina" Research Facility located in Salcha, Alaska. Each animal was tethered to a 2m 
chain attached to individual houses; each animal had access to his/her own food and 
water. Ambient temperature during sampling was between -23°C to -15°C. Twenty 
animals were sampled and placed into categories o f runners (R), non-runners (NR), male 
runners and non-runners (MR and MNR) and female runners and non-runners (FR and 
FNR), respectively(Table 2.1). Ages o f the animals ranged from less than 1 year to just 
over 11 years. A total o f 12 non-neutered males and 8 non-spayed females comprised the 
two groups. All animals were healthy at the time o f sampling and were free o f prescribed 
medication except for one animal (Marvin) who received Thyroxin" 1.2 mg B.I.D. for 
hypothyroidism.
Table 2.1. Animals used in the study listed with their age, sex, breed and grouping, 
respectively.
ANIMAL NAME GROUP AGE (yrs) SEX BREED
Brown R 5 M Alaskan Sled Dog
Mocha R 2 M Alaskan Sled Dog
Boney R 2 M Alaskan Sled Dog
Bruce R 2 M Alaskan Sled Dog
Nigel R 2 M Alaskan Sled Dog
Finnmark R 1 M Alaskan Sled Dog
Tromso R 1 M Alaskan Sled Dog
Dori R 2 F Alaskan Sled Dog
Peach R 2 F Alaskan Sled Dog
Hera R 6 F Alaskan Sled Dog
AVERAGE 2.5 70%M
Rambo NR 12 M Alaskan Sled Dog
Jose NR 1 M Alaskan Sled Dog
Apollo NR 1 M Alaskan Sled Dog
Sully NR 2 M Alaskan Sled Dog
Marvin NR 9 M Alaskan Sled Dog
Roz NR 2 F Alaskan Sled Dog
Pin NR 4 F Alaskan Sled Dog
Celia NR 2 F Alaskan Sled Dog
Lucy NR 12 F Alaskan Sled Dog
Twister NR 4 F Alaskan Sled Dog
AVERAGE 4.9 50%M
* All anim al ages are rounded  to  the nearest w hole  num ber
2.2 Animal Activity Levels
Control dogs remained tethered to their houses and activity levels varied with the 
individual dog. Runner dogs were exercised daily for approximately 0.5 h.
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2.3 Blood Sampling
Sampling o f dogs was conducted at the Nestle Purina" Research Facilities. All dogs were 
subjected to cephalic venipuncture using a 21G X 3/4 winged infusion set by Terumo" in 
connection with 12cc syringes. Approximately 10ml o f whole blood was collected from 
each animal and placed into 12cc herparinized vacutainer tubes. The samples were placed 
on ice and transported to the biochemistry laboratory at the University o f Alaska 
Fairbanks Natural Sciences Facility where they were subjected to centrifugation at 
lOOOXg for 15min. Plasma was collected and transferred into freezer vials and stored at 
-70°C until they were analyzed.
2.4 Biochemical Analysis
The biochemical analysis o f Vascular Endothelial Growth Factor was conducted at the 
University o f Alaska Fairbanks Natural Science Facility biochemistry laboratory. A 
commercial available ELISA Quanikine“ human VEGF Immunoassay was used from 
R&D Systems" (Cat# DVE00, Lot 225301). The assay was utilized to quantitatively 
evaluate circulatory levels o f VEGF in all o f the sampled animals. The Procedure 
supplied by R&D Systems" was followed (Cat# DVE00). A summary o f assay protocol 
is provided in figure 2.1. For the entire blood collection, all samples were analyzed using 
one assay kit. This approach was utilized to reduce variability and reagent related
differences, therefore comparisons were only made between samples which were 
collected at the same time and analyzed at the same time using one assay. Ages o f the 
subjects animals were all rounded to the nearest whole number (Table 3.1-3.8).
Table 2.2. Intra-assay and Inter-assay precision and variation among samplings in 
humans.
INTRA-ASSAY
PRECISION
INTER-ASSAY
PRECISION
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/ml) 53.7 235 910 64.5 250 1003
STDEV 3.6 10.6 46.2 5.7 17.4 61.7
CV (%) 6.7 4.5 5.1 8.8 7 6.2
Three human samples o f known concentration were tested twenty times on one plate to 
assess intra-assay precision. Three samples o f known concentration were tested in forty 
separate assays to assess inter-assay precision (DVEOO).
Figure 2.1. Overall schematic o f VEGF assay protocol and detection for ELISA 
Q uanikineR human VEGF Immunoassay from R&D Systems" (Cat# DVEOO, Lot 
225301).
,Optical density (OD) o f each sample was determined using Benchm ark" Microplate 
Reader from BioRad “. The VEGF concentrations for each sample were extrapolated 
using a standard curve (Figure 2.2) developed from known concentrations o f VEGF; the 
standard samples were human VEGF and assayed in parallel with the canine samples; all 
samples (including standards) were run in duplicate.
Figure 2.2. Standard curve used for concentration calculations
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2.5 Statistical Analysis
Analysis o f variance was used to evaluate any statistical differences between the groups. 
The F test was use to determine if  significant differences were present within standard 
deviations. No significant differences between standard deviations. Since there were no 
significant differences in the standard deviation, a simplified Student’s T test was utilized 
to evaluate group data. Significant differences were observed between two groups (Male 
vs. Female and Male runner vs. Female runners), the remaining groups displayed no 
significant differences.
34
Chapter 3 
RESULTS
In order to establish baseline levels for VEGF in healthy dogs, we analyzed plasma 
samples to establish concentrations and then analyzed established grouping within the 
studies overall sample size. The groupings were as follow: Runners, Non-runners, Male 
and Female, respectively. The various groupings were evaluated using analysis of 
variance and differences between the dog groupings were considered to be significant at 
p < 0.05.
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3.1 Overall Sampling of Healthy Dogs
Overall mean VEGF levels for all dogs analyzed were higher (19 pg/ml) than originally 
anticipated; however, a consistent pattern is observed within the VEGF concentrations.
VEGF PLASMA LEVELS: ALL DOGS
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Figure 3.1. VEGF Plasma levels in all dogs.
While there are various clusters o f VEGF levels for the dogs within the overall group, 
there appears to be a wide range o f concentrations among dogs. These clusters and 
separations, which are clearly displayed when looking at the mean and standard 
deviation, will be analyzed further in coming sections in order to elucidate any additional 
information regarding sub-grouping comparison and significance.
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Table 3.1. Values (pg/ml) o f VEGF plasma levels for each dog involved in the overall 
grouping.
GROUP AGE SEX BREED CONCENTRATION
ALL SAMPLES
Brown 4 M Sled Dog 17.33
Mocha 2 M Sled Dog 14.00
Boney 2 M Sled Dog 17.33
Bruce 2 M Sled Dog 21.50
Nigel 2 M Sled Dog 33.17
Finnmark 1 M Sled Dog 24.83
T romso 1 M Sled Dog 34.00
Dori 2 F Sled Dog 17.33
Peach 2 F Sled Dog 17.33
Hera 5 F Sled Dog 11.50
Rambo 12 M Sled Dog 28.17
Apollo 1 M Sled Dog 19.00
Jose 1 M Sled Dog 23.17
Sully 3 M Sled Dog 15.67
Marvin g M Sled Dog 12.33
Roz 2 F Sled Dog 15.67
Pin 4 F Sled Dog 19.83
Celia 2 F Sled Dog 13.17
Lucy 12 F Sled Dog 21.50
Twister 4 F Sled Dog 9.00
AVERAGE 3.7 60%M 19.29
STDEV 3.41 6.75
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3.2 Males vs. Females
Male and female dogs (both runners and non-runners) were compared. Male dogs 
displayed higher levels o f VEGF as compared to the female. The difference between the 
two groups was statistically evaluated and found to be significant at p < 0.05 (Table 3.2).
MEAN VEGF PLASMA LEVELS: MALE VS. 
FEMALE
Figure 3.2. Means and standard deviations o f VEGF plasma levels in male (running and
non-running) and female (running and non-running) dogs.
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Tab le  3.2. Values (pg/ml) o f VEGF plasma levels for both male and female dogs.
GROUP AGE SEX BREED CONCENTRATION
MALES
Brown 4 M Sled Dog 17.33
Mocha 2 M Sled Dog 14.00
Boney 2 M Sled Dog 17.33
Bruce 2 M Sled Dog 21.50
Nigel 2 M Sled Dog 33.17
Finnmark 1 M Sled Dog 24.83
Tromso 1 M Sled Dog 34.00
Rambo 12 M Sled Dog 28.17
Apollo 1 M Sled Dog 19.00
Jose 1 M Sled Dog 23.17
Sully 3 M Sled Dog 15.67
Marvin 9 M Sled Dog 12.33
AVERAGE 3.3 100%M 21.71
STDEV 3.5 7.17
GROUP AGE SEX BREED CONCENTRATION
FEMALE
Dori 2 F Sled Dog 17.33
Peach 2 F Sled Dog 17.33
Hera 5 F Sled Dog 11.50
Roz 2 F Sled Dog 15.67
Pin 4 F Sled Dog 19.83
Celia 2 F Sled Dog 13.17
Lucy 12 F Sled Dog 21.50
Twister 4 F Sled Dog 9.00
AVERAGE 4.1 100% 15.67
STDEV 3.4 4.23
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3.3 Runners vs. Non-Runners
Comparison o f the exercising animals, both males and females, showed slightly elevated 
levels (Table 3.3) in the exercising group. However, the elevated levels o f the exercising 
group were not statistically significant. The slight elevation in the runners could be due to 
the increased metabolic demand o f exercise or the larger number in the exercising group.
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Figure 3.3. Means and standard deviations o f VEGF levels for exercising and non­
exercising dogs (male and female).
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Table 3.3. Values (mg/pg) o f VEGF levels for exercising (runners) and non-exercising 
(non-runners) dogs.
GROUP AGE SEX BREED
CONCENTRATION
(pg/ml)
RUNNERS
Brown 4 M Sled Dog 17.33
Mocha 2 M Sled Dog 14.00
Boney 2 M Sled Dog 17.33
Bruce 2 M Sled Dog 21.50
Nigel 2 M Sled Dog 33.17
Finnmark 1 M Sled Dog 24.83
T romso 1 M Sled Dog 34.00
Dori 2 F Sled Dog 17.33
Peach 2 F Sled Dog 17.33
Hera 5 F Sled Dog 11.50
AVERAGE 2.3 67%M 20.83
STDEV 1.3 7.64
GROUP AGE SEX BREED CONCENTRATION
NON-RUNNERS
Rambo 12 M Sled Dog 28.17
Apollo 1 M Sled Dog 19.00
Jose 1 M Sled Dog 23.17
Sully 3 M Sled Dog 15.67
Marvin 9 M Sled Dog 12.33
Roz 2 F Sled Dog 15.67
Pin 4 F Sled Dog 19.83
Celia 2 F Sled Dog 13.17
Lucy 12 F Sled Dog 21.50
Twister 4 F Sled Dog 9.00
AVERAGE 5 50% M 17.75
STDEV 4.4 5.71
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3.4 Male Runners vs. Male Non-Runners
Comparison o f male exercising and non-exercising dogs were consistent with the overall 
elevation between running dogs and non-running dogs, displaying a slight elevation (but 
insignificant) in VEGF plasma levels in the running group (Figure 3.4). It is important to 
note there is an age variation between the 2 groups with the runners (mean age = 2) being 
younger than the non-runners (mean age = 5).
MEAN VEGF LEVELS: MALES
Male Runners Male Non-Runners
Figure 3.4. Means and standard deviations o f VEGF plasma levels o f male dogs (both 
runners and non-runners).
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T ab le  3.4. Values (pg/ml) o f VEGF for male dogs who were runners and for male dogs 
who were non-runners.
GROUP AGE SEX BREED CONCENTRATION
MALE RUNNERS
Brown 4 M Sled Dog 17.33
Mocha 2 M Sled Dog 14 00
Boney 2 M Sled Dog 17.33
Bruce 2 M Sled Dog 21.50
Nigel 2 M Sled Dog 33.17
Finnmark 1 M Sled Dog 24.83
Tromso 1 M Sled Dog 34.00
AVERAGE 2 100%M 23.17
STDEVA 1.0 7.90
GROUP AGE SEX BREED CONCENTRATION
MALE NON-RUNNERS
Rambo 12 M Sled Dog 28.17
Apollo 1 M Sled Dog 19.00
Jose 1 M Sled Dog 23.17
Sully 3 M Sled Dog 15.67
Marvin 9 M Sled Dog 12.33
AVERAGE 5 100%M 19.67
STDEVA 5.0 6.21
r
3.5 Female Runners vs. Female Non-Runners
Comparison o f female runners and non-runners is different from previous patterns of 
elevated VEGF plasma levels with running dogs having a lower VEGF mean (Figure 
3.5). No significant difference was observed upon statistical analysis.
MEAN VEGF PLASMA LEVELS: FEMALE
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Female Runners Female Non-Runners
Figure 3.5. Means and standard deviations o f VEGF plasma levels o f all female dogs 
(both runners and non-runners).
44
Table 3.5. Values (pg/ml) o f VEGF for all female dogs (both runners and non-runners).
GROUP AGE SEX BREED CONCENTRATION
FEMALE RUNNERS
Dori 2 F Sled Dog 17.33
Peach 2 F Sled Dog 17.33
Hera 5 F Sled Dog 11.50
AVERAGE 3 100%F 15.39
STDEV 1.7 3.37
GROUP AGE SEX BREED CONCENTRATION
FEMALE NON­
RUNNERS
Roz 2 F Sled Dog 15.67
Pin 4 F Sled Dog 19.83
Celia 2 F Sled Dog 13.17
Lucy 12 F Sled Dog 21.50
Twister 4 F Sled Dog 9.00
AVERAGE 4.8 100%F 15.83
STDEV 4.2 5.05
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3.6 Male Runners vs. Female Runners
VEGF levels in male and female runners were consistant with previous data showing 
male dogs having elevated levels when compared to females (Figure 3.2; Table 3.2). The 
differences between the male runners and the female runners were considered to be 
statistically significant at p < 0.05 (Table 3.6).
MEAN VEGF PLASMA LEVELS: MALE/FEMALE 
RUNNERS
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Figure 3.6. Means and standard deviations o f VEGF plasma levels in male and female
running dogs.
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Table 3.6. Values (pg/ml) o f VEGF for male and female running dogs.
GROUP AGE SEX BREED CONCENTRATION
MALE RUNNERS
Brown 4 M Sled Dog 17.33
Mocha 2 M Sled Dog 14.00
Boney 2 M Sled Dog 17.33
Bruce 2 M Sled Dog 21.50
Nigel 2 M Sled Dog 33.17
Finnmark 1 M Sled Dog 24.83
Tromso 1 M Sled Dog 34.00
AVERAGE 2 100%M 23.17
STDEVA 1.0 7.91
GROUP AGE SEX BREED CONCENTRATION
FEMALE RUNNERS
Dori 2 F Sled Dog 17.33
Peach 2 F Sled Dog 17.33
Hera 5 F Sled Dog 11.50
AVERAGE 3 100%F 15.39
STDEVA 1.7 3.37
r
3.7 Male Non-Runners vs. Female Non-Runners
VEGF levels for male and female non-running dogs were consistant with previous data 
(Figure 3.6; Table 3.6), having lower levels compared to running dogs, and female dogs 
displaying lower levels than the males. However, the differences were not statistically 
determined to be significant (Table 3.7). In this group, age does not appear to be a factor.
47
MEAN VEGF PLASMA LEVELS: MALE/FEMALE 
NON-RUNNERS
Male Non-runners Female Non-runners
Figure 3.7. Means and standard deviations o f VEGF plasma levels o f male and female
non-running dogs.
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T ab le  3.7. Values (pg/ml) o f VEGF for both male and female non-running dogs.
GROUP AGE SEX BREED CONCENTRATION
MALE NON-RUNNERS
Rambo 12 M Sled Dog 28.17
Apollo 1 M Sled Dog 19.00
Jose 1 M Sled Dog 23 17
Sully 3 M Sled Dog 15.67
Marvin 9 M Sled Dog 12.33
AVERAGE 5.2 100%M 19.67
STDEVA 5.0 6.22
GROUP AGE SEX BREED CONCENTRATION
FEMALE NON­
RUNNERS
Roz 2 F Sled Dog 15.67
Pin 4 F Sled Dog 19.83
Celia 2 F Sled Dog 13.17
Lucy 12 F Sled Dog 21.50
Twister 4 F Sled Dog 9.00
AVERAGE 4.8 100%F 15.83
STDEVA 4.2 5.05
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3.8 Healthy Dogs vs. Dog With Tumor
Samples from four healthy female non-running beagles were compared with one dog 
diagnosed with have a mammary gland tumor. While sample size is certainly an issue 
when evaluating data, the following figure is provided solely for further discussion on 
future research directions. The VEGF levels are lower than observed in sled dogs 
suggesting that baselines for individual breeds are needed for medical diagnosis. The 
mean for the healthy female dogs was 5 pg/ml (n=4).
VEGF LEVELS: TUMOR VS. HEALTHY CANINES
18
o>a
co
coucoO
Individual Animals
Figure 3.8. Values (pg/ml) o f four healthy (non-running) dogs with one dog diagnosed 
with a vascular tumor.
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Chapter 4
DISCUSSION AND FUTURE DIRECTION
Circulatory VEGF was readily detectable in all o f the dogs sampled. In this study the 
mean VEGF concentration was 19 pg/ml (Table 3.1), with the lowest detected 
concentration being 9 pg/ml and the highest concentration being 34 pg/ml (Table 3.1).
MEAN VEGF PLASMA LEVELS: ALL
Female Runners Male Runners Female Non- Male Non­
Runners Runners
Figure 4.1. Overall comparison o f means and standard deviations for all male and female 
runners and non-runners.
The males o f the study displayed an overall higher mean elevation in VEGF levels 
compared to the females; likewise, the runners had a higher mean concentration than non­
runners. To elucidate any significance, the groupings were broken down into categories 
o f runners, non-runners, female, male, male runners and non-runners and female runners
and non-runners, respectively. However, these various groups led to differences in mean 
age and gender. These factors must be considered when interpreting the data.
4.1 Runners vs Non-Runners
The mean VEGF concentrations for the two groups were 20.8 pg/ml for the runners and
17.8 pg/ml for the non-runners, respectively. Concentrations ranged from 34 pg/ml to 9 
pg/ml for both groups (Figure 3.3; Table 3.3). Although the sample size (n=12; Table 
3.3) for the two groups was the same, the inconsistency o f average age and gender within 
the samplings may explain why the difference was not statistically significantly. It is 
interesting to note that these elevated levels o f VEGF are consistent with the findings o f 
Kraus et al. (2004), where he and colleagues reported differences in VEGF levels in 
endurance athletes (human marathon runners) when compared to the sedentary 
individuals.
4.2 Male Runners vs Male Non-Runners
The mean VEGF concentrations for the male runners and non-runners was 23.2 pg/ml 
and 19.7 pg/ml (Figure 3.4; Table 3.4), respectively. The range for the male runners was 
as low as 14 pg/ml and as high as 34 pg/ml (Table 3.4). The non-runners display a similar 
range with levels o f 12.3 to 28.2 pg/ml (Table 3.4). Sample representation was consistent
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with n=7 for the running males and n=5 for the non-running males. Upon statistical 
evaluation, no significant difference was found between the two groups.
4.3 Female Runners vs Female Non-Runners
The female runners and non-runners definitely displayed lower levels o f VEGF plasma 
concentrations when compared to the males. As a group, both runners and non-runners, 
the females displayed fairly consistent VEGF levels (Figure 3.5; Table 3.5). The running 
group had a mean concentration o f 15.4 pg/ml and the non-running group mean 
concentration was 15.8 pg/ml. This is the opposite o f expectations that the running 
groups should have higher VEGF concentrations when compared to the non-runners. The 
running group had a sample size o f n=3 while the non-running group n=5. It is interesting 
to note that the two highest concentrations contributing to the higher mean in the non­
runners were the oldest dogs in the grouping (Table 3.5); however, no significant 
difference correlation VEGF levels and age was observed. Statistical evaluation between 
female runners and non-runners did not reach significance.
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4.4 Male vs Female
Male dogs when compared to the female dogs seemed to have the second greatest VEGF 
difference between the various groupings analyzed. Mean VEGF levels for the males was
21.7 pg/ml while the female levels were much lower, 15.7 pg/ml (Figure 3.2; Table 3.2). 
Male sampling was n=12 and the female sampling was n=8 (Table 3.2). Male 
concentrations ranged form 12.3 pg/ml to 34 pg/ml, while female samples ranged in 
concentration from 9 pg/ml to 21.5 pg/ml (Table 3.5). The differences between the male 
and female groups were found to be statistically significant at p < 0.05, and there was 
little age difference between the two groups.
4.5 Male Runners vs Female Runners
Concentrations for male runners were significantly higher than those o f the female 
runners. The mean male concentration o f VEGF was 23.2 pg/ml and the female mean 
concentration was 15.4 pg/ml (Figure 3.6; Table 3.6). This was the greatest difference 
observed between groupings but the female sample size was small. The concentrations 
for the male runners ranged from 14 pg/ml to 34 pg/ml, while the female concentrations 
ranged from 11.5 pg/ml to 17.3 pg/ml (Table 3.6). The male running sample size was 
over twice that o f the female (Table 3.6) with male n=7 and female n=3. The difference 
in the mean concentrations between the two groups was found to be statistically
significant at p < 0.05. Gender needs to be taken into consideration when VEGF levels 
are being used for health related diagnostics.
4.6 Male Non-Runners vs Female Non-Runners
The non-runners for the male and female groups were similar in their concentrations 
range: 12.3 pg/ml to 28.2 pg/ml for the males and 9 pg/ml to 21.5 pg/ml (Table 3.7). The 
mean concentrations for the two groups was only slightly different, 19.7 pg/ml for the 
males and 15.83 pg/ml for the females (Figure 3.7; Table 3.7). Both male and female 
non-runners had n=5. The difference between the two groups was not statistically 
significant, possibly due to the lower sample size and the standard deviation o f the assay.
4.7 VEGF Baseline Levels
There is a wealth o f physiological research establishing that skeletal muscle capillary 
density is an important factor when evaluating athletic maximum exercise capacity. 
Furthermore, it has long been established that endurance athletes, such as marathon 
runners and cyclists, have higher muscle capillary supplies when compared to individuals 
whom exercise modestly or not at all. Recent reports by Kraus and colleagues (2004) 
suggest that exercise-induced angiogenesis is mediated in part by the secretion o f VEGF 
via skeletal muscle cells. Kraus and colleagues (2004) study was conducted using human 
endurance athletes. They reported a 2-fold increase in the VEGF plasma levels shortly
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after exercise when comparing endurance athletes to sedentary individuals. The animals 
used in our study were all racing sled dogs, some o f which were retired and no longer 
running or actively training; however, at some stage in their life, all the dogs sampled 
were endurance trained athletes. One would expect a similar relationship in these athletic 
dogs. In comparison to human athletes, if  systemic VEGF levels in human athletes was 
observable at levels two times that o f sedentary individuals one would expect to see an 
even bigger increase o f VEGF shortly after exercising. Maximal sustained metabolic 
rates o f sled dogs have been measured well above those measure rates for human athletes. 
The small data set on healthy beagles (Figure 3.8) with VEGF levels around 5 pg/ml 
suggests that size may relate to muscle mass and, in turn, VEGF plasma levels.
To date there is a limited amount o f data available concerning canine VEGF in healthy 
dogs. It is rather surprising considering there are numerous studies o f VEGF levels in 
tumor ridden animals. Most o f the studies have concentrated their efforts on changes in 
VEGF levels in response to radiation and chemotherapy. It is important to note that our 
study has shown that VEGF levels appear to be dependant upon the gender o f the animal 
and the anim al’s level o f exercise. Establishing baseline levels for both sedentary and 
exercising animals will provide valuable insight into the further elucidation o f how 
VEGF protein levels respond to insult, as is focal limb ischemia, wound healing, 
menstruation and neoplasia.
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4.8 VEGF As A Diagnostic Tool
VEGF has been widely shown in human and animal (mostly rat) studies to increase in 
response to a developing growth or tumor. It is certainly plausible that detection of 
increased VEGF levels in the blood stream could lead to an early suspicion o f tumor 
growth and presence, or at least, suggest further analysis to investigate whether or not a 
growth is present. Having this information at the beginning stages o f disease would lead 
to early treatment and management o f canine cancer.
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